Differential requirements of sodium for coupling of cannabinoid receptors to adenylyl cyclase in rat brain membranes.
Sodium is generally required for optimal inhibition of adenylyl cyclase by Gi/o-coupled receptors. Cannabinoids bind to specific receptors that act like other members of the Gi/o-coupled receptor superfamily to inhibit adenylyl cyclase. However, assay of cannabinoid inhibition of adenylyl cyclase in rat cerebellar membranes revealed that concentrations of NaCl ranging from 0 to 150 mM had no effect on agonist inhibition. This lack of effect of sodium was not unique to cannabinoid receptors, because the same results were observed using baclofen as an agonist for GABAB receptors in cerebellar membranes. The lack of sodium dependence was region-specific, because assay of cannabinoid and opioid inhibition of adenylyl cyclase in striatum revealed an expected sodium dependence, with 50 mM NaCl providing maximal inhibition levels by both sets of agonists. This difference in sodium requirements between these two regions was maintained at the G protein level, because agonist-stimulated low Km GTPase activity was maximal at 50 mM NaCl in striatal membranes, but was maximal in the absence of NaCl in cerebellar membranes. Assay of [3H]WIN 55212-2 binding in cerebellar membranes revealed that the binding of this labeled agonist was sensitive to sodium and guanine nucleotides like other Gi/o-coupled receptors, because both NaCl and the nonhydrolyzable GTP analogue Gpp(NH)p significantly inhibited binding. These results suggest that differences in receptor-G protein coupling exist for cannabinoid receptors between these two brain regions.
Pacheco
M A
MA
Department of Physiology and Pharmacology, Bowman Gray School of Medicine, Winston-Salem, North Carolina 27157.
Ward
S J
SJ
Childers
S R
SR
D000262:Adenylyl Cyclases / Q000378:metabolism*; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D001418:Baclofen / Q000494:pharmacology; D048588:Benzoxazines; D001921:Brain / Q000378:metabolism*; D002186:Cannabinoids / Q000494:pharmacology*; D002531:Cerebellum / Q000378:metabolism; D003342:Corpus Striatum / Q000378:metabolism; D003511:Cyclohexanols / Q000494:pharmacology; D019204:GTP-Binding Proteins / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D009025:Morpholines / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000378:metabolism*; D018080:Receptors, GABA-B / Q000378:metabolism; D012964:Sodium / Q000494:pharmacology*; D012965:Sodium Chloride / Q000494:pharmacology*
D000700:Analgesics; D048588:Benzoxazines; D002186:Cannabinoids; D003511:Cyclohexanols; D009025:Morpholines; D009281:Naphthalenes; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D018080:Receptors, GABA-B; D012965:Sodium Chloride; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; D012964:Sodium; D019204:GTP-Binding Proteins; D000262:Adenylyl Cyclases; D001418:Baclofen